NTLA:NASDAQ
Intellia Therapeutics Inc
US$13.71
arrow_upward
+3.39%(+0.45) 1 天
5月4日, GMT-4 11:53:52 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 NTLA 生成关键数据洞见…
开盘价
US$13.31
最高价
US$14.07
最低价
US$13.31
市值
一八.三四亿
成交量
二七二.五八万
52 周最高价
US$28.25
52 周最低价
US$6.83
每股收益
-US$3.81
Beta 版
一.九三
流通股数
一.一八亿
员工人数
三七七
新闻报道
来自全网
Quiver Quantitative
·
1小时前
$NTLA stock is up 4% today. Here's what we see in our data.
Stock Traders Daily
·
21小时前
Behavioral Patterns of NTLA and Institutional Flows
资料
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc简介